- Global Pharma News & Resources

LFB Plasma Establishes Third Location in the U.S.; Acquires ImmunoTek Bio Center in Florence, South Carolina

LFB, a global bio-pharmaceutical group that develops and markets therapeutics for patients with chronic and serious diseases in 30 countries, opens it’s first location in South Carolina as “LFB Plasma.”

FLORENCE, S.C.--(BUSINESS WIRE)--LFB Plasma ( announced today the acquisition of another ImmunoTek Bio Center location, its first in South Carolina, located at 1933 2nd Loop Rd., Florence, SC 29501. LFB Plasma is part of the LFB Group, a global bio-pharmaceutical company that develops and provides plasma derived and recombinant products through its innovative technologies to patients with chronic and serious diseases. The acquisition of the Florence center is the first LFB Plasma collection site in South Carolina and its third site in the U.S. continuing LFB’s establishment of a reliable and consistent supply of U.S. sourced plasma.

Jose Antonio Moreno Toscano, LFB USA’s CEO, said today, “We are excited about our expansion into South Carolina, and we look forward to a successful transition of the ImmunoTek center in Florence. We are thankful for the staff who have participated in the build-up of this center; all 18 employees will be transferred over to LFB and will benefit from being part of our global bio-pharmaceutical company. We emphasize community growth and development and hope to make a long-term and sustainable economic impact on the city of Florence. Ultimately, each donation of plasma has the potential to provide a lifesaving treatment to those in need; the compensation to donors represents our gratitude for the commitment they make to help save lives.”

ImmunoTek Bio Centers was responsible for constructing and operating the Florence center since it opened in 2017. “We are pleased to reach this significant milestone in our cooperative partnership with LFB and are looking forward to a strong business alliance that increases access to life-saving plasma,” said Jerome Parnell III, CEO & President of ImmunoTek.

About LFB Group

LFB is a biopharmaceutical group that develops, manufactures and markets plasma-derived medicinal products and recombinant proteins for the treatment of serious and often rare diseases. Created in France in 1994, LFB is today one of the leading European companies providing plasma-derived and recombinant medicinal products to healthcare professionals. Its mission is to offer patients new treatment options for unmet needs in three major therapeutic areas: immunology, haemostasis and intensive care. LFB’s current market portfolio includes 15 biomedicinal products sold in about 30 countries. -

LFB plasma donors are compensated for each donation, and they make and receive basic health monitoring as part of that experience.

About ImmunoTek

ImmunoTek Bio Centers LLC is the fastest growing independent plasma collection center operator in the United States and is a global leader in developing a reliable plasma supply chain for bio-pharmaceutical companies. ImmunoTek and its predecessor company have built and operated more than 150 FDA-licensed and EU-certified plasma collection centers, with nearly 60 additional centers currently in progress. For more information –

LFB USA’s CEO Jose Antonio Moreno Toscano is available for interviews.


Jen Foland
Fahrenheit Agency

Editor Details

  • Company:
    • Businesswire
Last Updated: 07-Dec-2021